Talha Mubashir1, Mahesh Nagappa2, Nilufar Esfahanian1, Joseph Botros1, Abdul A Arif1, Colin Suen1, Jean Wong1,3, Clodagh M Ryan4, Frances Chung1. 1. Department of Anesthesia and Pain Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada. 2. Department of Anesthesia and Perioperative Medicine, London Health Sciences Centre and St. Joseph Health Care, Western University, London, Ontario, Canada. 3. Department of Anesthesia and Pain Medicine, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. 4. Centre of Sleep Health and Research, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Abstract
STUDY OBJECTIVES: Opioids have been reported to increase the risk for sleep-disordered breathing (SDB) in patients with noncancer chronic pain on opioid therapy. This study aims to determine the pooled prevalence of SDB in opioid users with chronic pain and compare it with patients with pain:no opioids and no pain:no opioids. METHODS: A literature search of PubMed, Medline, Embase, and Cochrane Central Register of Controlled Trials was conducted. We included all observational studies that reported the prevalence of SDB in patients with chronic pain on long-term opioid therapy (≥3 months). The primary outcome was the pooled prevalence of SDB in opioid users with chronic pain (pain:opioids group) and a comparison with pain:no opioids and no pain:no opioids groups. The meta-analysis was performed using a random-effects model. RESULTS: After screening 1,404 studies, 9 studies with 3,791 patients were included in the meta-analysis (pain:opioids group, n = 3181 [84%]; pain:no opioids group, n = 359 [9.4%]; no pain:no opioids group, n = 251 [6.6%]). The pooled prevalence of SDB in the pain:opioids, pain:no opioids, and no pain:no opioids groups were 91%, 83%, and 72% in sleep clinics and 63%, 10%, and 75% in pain clinics, respectively. Furthermore, in the pain: opioids group, central sleep apnea prevalence in sleep and pain clinics was 33% and 20%, respectively. CONCLUSIONS: The pooled prevalence of SDB in patients with chronic pain on opioid therapy is not significantly different compared with pain:no opioids and no pain:no opioids groups and varies considerably depending on the site of patient recruitment (ie, sleep vs pain clinics). The prevalence of central sleep apnea is high in sleep and pain clinics in the pain:opioids group. Clinical Trial Registration: Registry: PROSPERO: International prospective register of systematic reviews; Name: Prevalence of sleep disordered breathing, hypoxemia and hypercapnia in patients on oral opioid therapy for chronic pain management; URL: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018103298; Identifier: CRD42018103298.
STUDY OBJECTIVES: Opioids have been reported to increase the risk for sleep-disordered breathing (SDB) in patients with noncancer chronic pain on opioid therapy. This study aims to determine the pooled prevalence of SDB in opioid users with chronic pain and compare it with patients with pain:no opioids and no pain:no opioids. METHODS: A literature search of PubMed, Medline, Embase, and Cochrane Central Register of Controlled Trials was conducted. We included all observational studies that reported the prevalence of SDB in patients with chronic pain on long-term opioid therapy (≥3 months). The primary outcome was the pooled prevalence of SDB in opioid users with chronic pain (pain:opioids group) and a comparison with pain:no opioids and no pain:no opioids groups. The meta-analysis was performed using a random-effects model. RESULTS: After screening 1,404 studies, 9 studies with 3,791 patients were included in the meta-analysis (pain:opioids group, n = 3181 [84%]; pain:no opioids group, n = 359 [9.4%]; no pain:no opioids group, n = 251 [6.6%]). The pooled prevalence of SDB in the pain:opioids, pain:no opioids, and no pain:no opioids groups were 91%, 83%, and 72% in sleep clinics and 63%, 10%, and 75% in pain clinics, respectively. Furthermore, in the pain: opioids group, central sleep apnea prevalence in sleep and pain clinics was 33% and 20%, respectively. CONCLUSIONS: The pooled prevalence of SDB in patients with chronic pain on opioid therapy is not significantly different compared with pain:no opioids and no pain:no opioids groups and varies considerably depending on the site of patient recruitment (ie, sleep vs pain clinics). The prevalence of central sleep apnea is high in sleep and pain clinics in the pain:opioids group. Clinical Trial Registration: Registry: PROSPERO: International prospective register of systematic reviews; Name: Prevalence of sleep disordered breathing, hypoxemia and hypercapnia in patients on oral opioid therapy for chronic pain management; URL: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018103298; Identifier: CRD42018103298.
Authors: Jan J Barendregt; Suhail A Doi; Yong Yi Lee; Rosana E Norman; Theo Vos Journal: J Epidemiol Community Health Date: 2013-08-20 Impact factor: 3.710
Authors: Ilene M Rosen; R Nisha Aurora; Douglas B Kirsch; Kelly A Carden; Raman K Malhotra; Kannan Ramar; Fariha Abbasi-Feinberg; David A Kristo; Jennifer L Martin; Eric J Olson; Carol L Rosen; James A Rowley; Anita V Shelgikar Journal: J Clin Sleep Med Date: 2019-11-15 Impact factor: 4.062
Authors: Julia Tárrega; Rosa Güell; Antonio Antón; Merce Mayos; Ariadna Farré; Francisco R Jerez; Joaquín Sanchis Journal: Respir Care Date: 2002-08 Impact factor: 2.258
Authors: Richard B Berry; Rohit Budhiraja; Daniel J Gottlieb; David Gozal; Conrad Iber; Vishesh K Kapur; Carole L Marcus; Reena Mehra; Sairam Parthasarathy; Stuart F Quan; Susan Redline; Kingman P Strohl; Sally L Davidson Ward; Michelle M Tangredi Journal: J Clin Sleep Med Date: 2012-10-15 Impact factor: 4.062
Authors: S-Hakki Onen; Fannie Onen; Gilles Albrand; Evelyne Decullier; François Chapuis; Claude Dubray Journal: J Am Med Dir Assoc Date: 2010-11 Impact factor: 4.669
Authors: Tetyana Kendzerska; Tara Gomes; Atul Malhotra; Andrea S Gershon; Marcus Povitz; Daniel I McIsaac; Shawn D Aaron; Frances Chung; Gregory L Bryson; Robert Talarico; Tahmid Ahmed; Michael Godbout; Peter Tanuseputro Journal: PLoS One Date: 2022-06-28 Impact factor: 3.752